Notice of the Annual General Meeting of Vitrolife AB (publ)

Notice of the Annual General Meeting of Vitrolife AB (publ) 

The following proposals will be amongst those presented at the Annual General
Meeting of Vitrolife AB on Monday April 26, 2010:

•	A dividend of SEK 0.50 per share and Thursday April 29, 2010 as the record day
for dividend.
  
•	It is proposed that Patrik Tigerschiöld, Madeleine Olsson-Eriksson, Fredrik
Mattsson, Maris Hartmanis and Tord Lendau be re-elected as members of the Board
and that Barbro Fridén (Director of the Children's Division at the Astrid
Lindgren Children's Hospital, Karolinska University Hospital) be elected as a
new member of the Board. The Board member Semmy Rülf has declined re-election.
It is proposed that Patrik Tigerschiöld be re-elected as Chairman of the Board.
Furthermore, it is proposed that Board fees of SEK 700,000 be paid, with SEK
200,000 to the Chairman of the Board and SEK 100,000 kronor to each of the other
members of the Board. 

•	A new Election Committee is to be appointed for the Annual General Meeting of
2011 in accordance with the previously applied model. This model means that the
Chairman of the Board is given the task of contacting the three largest
registered shareholders or otherwise known owners at the end of the third
quarter of 2010 and asking them to appoint one member each to the Election
Committee. If such a shareholder does not wish to appoint a member of the
Committee, the fourth largest shareholder is asked, and so on. The three members
who are thus appointed, together with the Chairman of the Board as the convener,
are to constitute the Election Committee.

•	Authorization for the Board to make a decision on the acquisition and transfer
of the company's own shares during the period up until the next Annual General
Meeting.

Attachment: Notice

Gothenburg, March 24, 2010

Vitrolife AB (Publ)


Queries should be addressed to: 
Patrik Tigershiöld, Chairman of the Board, phone +46 8 614 00 20
Eva Nilsagård, CFO, phone +46 31 721 80 13

________________________________________________________________________________
________________________________________________
Vitrolife is a global biotechnology/medical device Group that works with
developing, manufacturing and selling advanced products and systems for the
preparation, cultivation and storage of human cells, tissue and organs. The
company has business activities within three product areas: Fertility,
Transplantation and Stem Cell Cultivation. 
     The Fertility product area works with nutrient solutions (media),
cryopreservation products and advanced consumable instruments such as needles
and pipettes, for the treatment of human infertility. The Transplantation
product area works with solutions and systems to evaluate and maintain organs
outside the body order to select usable organs and keeping them in optimal
condition while waiting for transplantation. The Stem Cell Cultivation product
area works with media and instruments to enable the use and handling of stem
cells for therapeutic purposes. 
     Vitrolife today has approximately 170 employees and the company's products
are sold in more than 85 markets. The company is headquartered in Gothenburg,
Sweden, and there are subsidiaries in USA, Australia, France, Italy and Japan.
Production facilities are located in Sweden and USA. 
     The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.
________________________________________________________________________________
_________________________________________________
Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity
number 556354-3452.
Tel: +46 31 721 80 00. Fax: +46 31 721 80 99. E-mail: info@vitrolife.com.
Website: www.vitrolife.com.

Vitrolife is required to publish the information in this press release in
accordance with the Swedish Securities Market Act and/or the Financial
Instruments Trading Act. The information was submitted for publication on
Wednesday March 24, 2010 at 2:30 pm CET.

This is a translation of the Swedish version of the notice. When in doubt, the
Swedish wording prevails.